FDA Considers Leucovorin Approval for Subset of Autistic Individuals With Cerebral Folate Deficiency

The U.S. Food and Drug Administration (FDA) has taken an unusual step by initiating the approval process for leucovorin calcium tablets to treat cerebral folate deficiency (CFD) in some autistic individuals, as announced in September 2025. This marks one of few times the agency has pursued approval for a medication addressing neurological differences associated with autism, sparking debate about evidence standards.

Understanding Cerebral Folate Deficiency

CFD occurs when folate transport to the brain is impaired, affecting an estimated 5-10% of autistic individuals according to research cited by Frontiers. Unlike general folate deficiency, CFD specifically impacts neurological function while blood folate levels may appear normal.

However, as noted in Cureus's 2025 review, such limited samples make broader conclusions difficult.

What is Leucovorin?

Leucovorin (folinic acid) is a bioavailable folate form that crosses the blood-brain barrier. A small clinical trial (NCT02839915) involving just five participants suggested potential communication benefits for autistic individuals with CFD. However, as noted in Cureus's 2025 review, such limited samples make broader conclusions difficult.

Evidence and Regulatory Context

While some families report significant improvements - like one child whose communication expanded according to JHEOR - the FDA typically requires Phase 3 trials involving hundreds of participants for approval. 'We need to balance accessibility with scientific rigor,' one researcher told Neuroscience News.

Current Support Options

No medications currently address autism's neurological differences directly. The only FDA-approved autism-related medication, risperidone, manages co-occurring irritability rather than communication or sensory processing patterns (Autism.org). This reflects a broader trend where, as Frontiers notes, most pharmacological approaches target specific support needs rather than 'treating' autism itself.

Autistic self-advocate groups emphasize that any medical approach should prioritize individual needs over deficit-based models. 'Support should enhance quality of life without pathologizing neurodivergence,' notes the Autistic Self Advocacy Network.

Leucovorin's safety profile is well-established for other uses, though potential side effects include digestive discomfort and sleep disturbances (PMC). Its mechanism in CFD remains under study, with UMass research exploring biomarker identification to predict responsiveness.